Here are seven updates from gastroenterology companies from the past week:
GI & Endoscopy
The American College of Gastroenterology, American Gastroenterological Association, American Association for the Study of Liver Diseases and the American Society for Gastrointestinal Endoscopy provided guidance around how gastroenterologists should perform procedures during the COVID-19 pandemic.
Like COVID-19, colon cancer is an invisible disease that can be fatal; it is the second-leading cause of cancer death in the U.S. among men and women combined, according to AmSurg, a Nashville, Tenn.-based ASC management company.
The U.S. Multi-Society Task Force made a series of recommendations around endoscopic removal of colorectal cancer lesions in the March issue of The American Journal of Gastroenterology.
Exact Sciences joined a public-private partnership to increase COVID-19 laboratory testing capacity in Wisconsin, according to a March 30 announcement from the state.
Advertisement
The FDA warned clinicians the SARS-CoV-2 virus, which causes COVID-19, may be transmitted in fecal samples during fecal microbiota transplants.
Takeda partnered with Evox Therapeutics in a deal worth $882 million to develop up to five rare disease programs, Pharmaphorum reports.
Motus GI gained CE Mark approval for its GEN2 Pure-Vu System, a colonoscopy device designed to facilitate the cleaning of a poorly prepared colon, according to a March 27 announcement.
Four COVID-19 updates for gastroenterologists this week:
Gastroenterologists treating COVID-19 patients have a number of resources to help guide them, including statements from professional societies and dedicated websites with information on the virus.